n.a. (PCYC)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
ASCO '13 Preview: Gilead's Big Cancer Debut

ASCO '13 Preview: Gilead's Big Cancer Debut

More than half of patients responded to treatment with Gilead's idelalisib in a phase I study.

10 ASCO '13 Abstracts You Can Read Right Now

10 ASCO '13 Abstracts You Can Read Right Now

Get a head start on searching through ASCO abstracts with these 10 summaries.

Pharmacyclics Rises On Unusually High Volume (PCYC)

Pharmacyclics Rises On Unusually High Volume (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) is trading at unusually high volume Monday with 1.6 million shares changing hands. It is currently at two times its average daily volume and trading up $7.20 (+9.1%).

3 Biotech Stocks Spiking With Big Volume

3 Biotech Stocks Spiking With Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner

Pharmacyclics Incorporated was a winner within the drugs industry, rising $4.17 (5.4%) to $81.69 on average volume

Pharmacyclics Incorporated (PCYC): Drugs' Featured Daily Laggard

Pharmacyclics Incorporated (PCYC): Drugs' Featured Daily Laggard

Pharmacyclics Incorporated was a leading decliner within the drugs industry, falling $1.64 (-2.1%) to $75.12 on light volume.

Technical Outlook Darkens

Although the S&P remains close to its 2013 high, a recovery wave will probably fail, given deterioration in other market groups.

TheStreet Ratings Top 10 Rating Changes

TheStreet Ratings Top 10 Rating Changes

TheStreet Ratings released rating changes on 51 U.S. common stocks for week ending April 5, 2013. 30 stocks were upgraded and 21 stocks were downgraded by our stock model.

Pharmacyclics Incorporated Stock Downgraded (PCYC)

Pharmacyclics Incorporated Stock Downgraded (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) has been downgraded by TheStreet Ratings from from a buy to hold.

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard

Pharmacyclics Incorporated was a leading decliner within the drugs industry, falling $3.48 (-3.9%) to $86.62 on average volume.

INCY, PCYC, EW And A, 4 Health Care Stocks Pushing The Sector Lower

INCY, PCYC, EW And A, 4 Health Care Stocks Pushing The Sector Lower

TheStreet Ratings group would like to highlight 4 stocks pushing the health care sector lower today, March 19, 2013.

Pharmacyclics Incorporated (PCYC): Today's Featured Health Care Laggard

Pharmacyclics Incorporated (PCYC): Today's Featured Health Care Laggard

Pharmacyclics Incorporated was a leading decliner within the health care sector, falling $1.95 (-2.1%) to $92.25 on heavy volume.

5 Stocks Pushing The Health Care Sector Higher

5 Stocks Pushing The Health Care Sector Higher

TheStreet Ratings group would like to highlight 5 stocks pushing the health care sector higher today, March 6, 2013.

Pharmacyclics Stock Hits New 52-Week High (PCYC)

Pharmacyclics Stock Hits New 52-Week High (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) hit a new 52-week high Tuesday as it is currently trading at $92.48, above its previous 52-week high of $91.66 with 48,802 shares traded as of 9:41 a.m. ET. Average volume has been 627,600 shares over the past 30 days.

Pharmacyclics Reaches New 52-Week High (PCYC)

Pharmacyclics Reaches New 52-Week High (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) hit a new 52-week high Wednesday as it is currently trading at $87.90, above its previous 52-week high of $87.82 with 541,545 shares traded as of 12:40 p.m. ET. Average volume has been 591,000 shares over the past 30 days.

Pharmacyclics Rises On Unusually High Volume (PCYC)

Pharmacyclics Rises On Unusually High Volume (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) is trading at unusually high volume Wednesday with 1.1 million shares changing hands. It is currently at two times its average daily volume and trading up $5.84 (+8.3%).

3 Stocks Pushing The Drugs Industry Higher

3 Stocks Pushing The Drugs Industry Higher

TheStreet Ratings group would like to highlight 3 stocks pushing the drugs industry higher today, Feb. 13, 2013.

Pharmacyclics Reaches New 52-Week High (PCYC)

Pharmacyclics Reaches New 52-Week High (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) hit a new 52-week high Tuesday as it is currently trading at $71.94, above its previous 52-week high of $71.91 with 128,524 shares traded as of 10:26 a.m. ET. Average volume has been 552,000 shares over the past 30 days.

Ziopharm's Sarcoma Study and the Feuerstein-Ratain Rule

Ziopharm's Sarcoma Study and the Feuerstein-Ratain Rule

What does Ziopharm's market value say about the success of the sarcoma drug palifosfamide?

Pharmacyclics Incorporated Stock Upgraded (PCYC)

Pharmacyclics Incorporated Stock Upgraded (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) has been upgraded by TheStreet Ratings from a hold to buy.

Pharmacyclics Stock Hits New 52-Week High (PCYC)

Pharmacyclics Stock Hits New 52-Week High (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) hit a new 52-week high Thursday as it is currently trading at $70.63, above its previous 52-week high of $70.48 with 130,492 shares traded as of 9:52 a.m. ET. Average volume has been 736,900 shares over the past 30 days.

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard

Pharmacyclics Incorporated was a leading decliner within the drugs industry, falling $2.27 (-3.4%) to $65.15 on light volume.

Off the Charts

Off the Charts

It's encouraging now to see the S&P hold onto most of those post fiscal cliff gains.

Score Big On Top Line Growth Stocks

Score Big On Top Line Growth Stocks

A company that can continue to grow sales is creating value for its shareholders. However, strong top line growth isnâ¿¿t [...]

The Twitterverse's Biotech Stock Picks for 2013

The Twitterverse's Biotech Stock Picks for 2013

TheStreet's readers took to Twitter to offer their biotech stock predictions for 2013.

Best Biotech CEO of 2012: Your Vote Counts

Best Biotech CEO of 2012: Your Vote Counts

CEOs from Onyx Pharma, Gilead Sciences, Regeneron Pharma and Sarepta Therapeutics vie for title.

Biotech Stock Mailbag: YM Bio, Infinity, Delcath and Galena

Biotech Stock Mailbag: YM Bio, Infinity, Delcath and Galena

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

The Next Big Thing In Biotech: ASH Meeting

The Next Big Thing In Biotech: ASH Meeting

Adam Feuerstein, Sr. Columnist for TheStreet, says the American Society of Hematology meeting is the next big thing to watch in biotech.

Pharmacyclics Incorporated (PCYC): Today's Featured Health Care Winner

Pharmacyclics Incorporated (PCYC): Today's Featured Health Care Winner

Pharmacyclics Incorporated was a winner within the health care sector, rising $2.88 (5.4%) to $55.93 on average volume.

Two More to Short

Two More to Short

My list doubles in size.